These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24899102)

  • 1. Efficacy of zoledronic acid treatment in Paget disease of bone.
    Baykan EK; Saygılı LF; Erdogan M; Cetinkalp S; Ozgen AG; Yilmaz C
    Osteoporos Int; 2014 Sep; 25(9):2221-3. PubMed ID: 24899102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone.
    Tucci JR
    Endocr Pract; 2008; 14(5):607-10. PubMed ID: 18753106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZOLEDRONIC ACID THERAPY OF PATIENTS WITH PAGET DISEASE OF BONE RESISTANT TO OR WITH UNSUSTAINED REMISSION FOLLOWING PRIOR BISPHOSPHONATE THERAPY.
    Tucci JR
    Endocr Pract; 2015 Oct; 21(10):1111-6. PubMed ID: 26151420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission over 3 years in patients with Paget disease of bone treated with a single intravenous infusion of 5 mg zoledronic acid.
    Devogelaer JP; Geusens P; Daci E; Gielen E; Denhaerynck K; Macdonald K; Hermans C; Vancayzeele S; Abraham I; Boonen S
    Calcif Tissue Int; 2014 Mar; 94(3):311-8. PubMed ID: 24271562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA
    Clin Rheumatol; 2011 Jan; 30(1):149-50. PubMed ID: 21053036
    [No Abstract]   [Full Text] [Related]  

  • 8. Long term effects on biochemical bone markers of a single infusion of zoledronic acid in Paget disease of bone.
    Rodríguez-Olleros Rodríguez C; Blanes Jacquart D; Arboiro Pinel R; de la Piedra Gordo C; Moro Álvarez MJ; Díaz Curiel M
    J Orthop Sci; 2020 Jul; 25(4):715-718. PubMed ID: 31669119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paget disease of bone: therapeutic options.
    Silverman SL
    J Clin Rheumatol; 2008 Oct; 14(5):299-305. PubMed ID: 18838910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paget disease of bone - an update.
    Britton C; Walsh J
    Aust Fam Physician; 2012 Mar; 41(3):100-3. PubMed ID: 22396921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP; Manicourt DH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget disease of bone.
    Merlotti D; Rendina D; Gennari L; Mossetti G; Gianfrancesco F; Martini G; De Filippo G; Avanzati A; Franci B; Campagna MS; Strazzullo P; Nuti R
    J Bone Miner Res; 2011 Mar; 26(3):512-8. PubMed ID: 20814970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone.
    Woitge HW; Oberwittler H; Heichel S; Grauer A; Ziegler R; Seibel MJ
    Clin Chem; 2000 May; 46(5):684-90. PubMed ID: 10794751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
    Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy.
    Pane A
    Arch Ophthalmol; 2007 Oct; 125(10):1440-1. PubMed ID: 17923566
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment of Paget's disease of bone: importance of the zoledronic acid].
    Griz L; Colares V; Bandeira F
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):845-51. PubMed ID: 17160207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.